日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Sanofi targets ground-breaking therapies with a new R&D strategy

chinadaily.com.cn | Updated: 2022-03-31 11:04
Share
Share - WeChat
John Reed, executive vice-president, global head of research and development at Sanofi. [Photo provided to chinadaily.com.cn]

"We are sharpening our R&D focus on first-in-class or best-in-class medicines and vaccines in order to address the world's most urgent healthcare needs", said John Reed, executive vice-president and head of Global R&D of Sanofi. He emphasized Sanofi's scientific mission when talking about the company's R&D strategy, "because patients are counting on us."

Reed, formerly the head of Roche Pharma Research and Early Development (pRED), joined Sanofi in 2018, where he participated in and witnessed a crucial strategic transformation of the company.

As an essential step in Sanofi's "Play to Win" strategy, announced in 2019, the company launched a new brand identity and purpose to highlight its corporate mission "Chase the miracles of science to improve people's lives" early this year.

Companies that implement rebranding will often make key strategic adjustments, and Sanofi is no exception. As an R&D-driven pharmaceutical company, Sanofi has made the transformation of its R&D strategy central to its rebranding initiatives.

"The pursuit of scientific miracles is a dynamic process, and the process of R&D is challenging, but we don't let the setbacks deter us from pushing forward and working to improve the lives of patients," Reed said.

A new transformation, a new ambition

Founded in 1973, Sanofi is a young global pharmaceutical company. In the past several decades, it has developed many breakthrough therapies, including Lantus (insulin glargine), Taxotere (anti-cancer drug), Lovenox (anti-coagulant), Aubagio (multiple sclerosis), and Cerezyme (Gaucher disease).

For almost half a century, Sanofi has been protecting lives with its vaccines, saving and transforming lives with its cutting-edge science, from primary care to the treatment of cancer and rare diseases. It took Sanofi only 32 years to go from being a small company to being one of the top pharmaceutical giants in the world, an astonishingly rapid ascent compared with century-old pharmaceutical companies.

Despite such extraordinary past achievements, Sanofi is reflecting on the most urgent healthcare needs which have yet to be resolved. Can innovation and R&D be refocused? Can products have greater clinical value? How to sustain long-term growth? According to Reed, Sanofi has strictly prioritized and reallocated resources for R&D.

Based on its expertise and experience with preventing and treating conditions from chronic diseases to rare diseases, Sanofi further optimizes resources to sharpen its R&D focus to first-in-class or best-in-class programs in vaccines and specialty care areas like immunology and oncology, where recent breakthroughs open up a world of new therapeutic opportunities.

A sign of Sanofi's progress is that in 2021 it added 36 phase I and phase II clinical development programs, a clear indication of its strong pipeline of early-stage projects. The company is also investing more in biologics – seen in the fact that they now represent over 70 percent of its pipeline.

According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.

Sanofi's changes are also evident in its financial performance. In the newly released 2021 annual financial report, specialty medicine has become Sanofi's most prominent business unit by sales for the first time, with R&D investment in specialty drug products accounting for 95 percent of the company's total R&D investment, up by about 50 percent from that of 2017.

1 2 3 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 三级色视频 | 成人久久久 | 天天干天天操 | 99视频在线观看精品 | 亚洲一区二区在线 | 天天操天天操天天 | 日韩免费视频 | 奇米色第四色 | 国产人妻人伦精品潘金莲 | 91九色porn偷拍在线 | 久久综合久久精品 | 男人添女人下面免费网站 | 色综合天天天天做夜夜夜夜做 | 污污的网站免费在线观看 | 国产又黄又猛又粗又爽的A片动漫 | 达达兔午夜起神影院在线观看麻烦 | 欧美日韩久久久 | 欧美日韩中文字幕在线观看 | 一级黄色一级片 | 91免费影片| 91网视频在线观看 | 牛牛a级毛片在线播放 | 天堂一区 | 久久久久久久久女黄 | 久久女 | 日本高清视频在线播放 | 综合二区 | 激情五月色综合国产精品 | 欧美特黄一级视频 | 亚洲日韩视频 | 深夜网址你懂的 | 一级一片在线播放在线观看 | 国产精品区二区三区日本 | 一区二区三区四区不卡视频 | 国产成人av在线 | 欧美日韩高清一区 | 国产成人精品一区二区三在线观看 | 久久九色 | 碰碰碰精品视频在线观看 | 欧美激情视频网 | 青娱在线视频 |